{
    "symbol": "KURA",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-23 22:11:19",
    "content": " Notably, in our Phase 1 trial for ziftomenib two-thirds of NPM1-mutant AML patients who achieved a CR at 600 milligrams had either IDH and/or FLT3 co-mutations, all of whom had failed prior treatment with IDH and/or FLT3 inhibitors. We intend to evaluate safety, tolerability and preliminary antitumor activity of KO-2806 in a Phase 1 dose-escalation trial, which we\u00e2\u0080\u0099re calling FIT-001 as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}